Curriculum Vitae
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
The Role of Intravenous Urography with Erect Film and Retrograde
Central Journal of Urology and Research Bringing Excellence in Open Access Research Article *Corresponding author Ahmed N. Ghanem, Department of Urology, Consultant Urologist Surgeon, No1 President Mubarak The Role of Intravenous Street, Mansoura 35511, Egypt, Tel: 001020883243; Email: Submitted: 05 November 2018 Urography with Erect Film and Accepted: 22 November 2018 Published: 26 November 2018 Retrograde Pyelography in ISSN: 2379-951X Copyright © 2018 Ghanem et al. Revealing Patho-Etiology of OPEN ACCESS Keywords the Loin Pain and Haematuria • Intravenous urography • Retrograde pyelography • Loin pain haematuria syndrome Syndrome by Discovering • Nephroptosis its Overlooked Link with Symptomatic Nephroptosis Khalid A Ghanem1, Salma A. Ghanem2, Nisha Pindoria3, and Ahmed N. Ghanem1* 1Department of Urology, Mansoura University Hospital, Egypt 2Department of Urology, Barts & The Royal London NHS Trust Royal London Hospital, Egypt 3Department of Urology, North Middlesex University Hospital, Egypt Abstract Introduction and objectives: To report the role of intravenous urography with erect film (IVU-E) and retrograde pyelography (RGP) in resolving the puzzle of Loin Pain and Haematuria Syndrome (LPHS) by revealing its patho-etiological overlooked link with Symptomatic Nephroptosis (SN). We demonstrate that renal pedicle stretch causes neuro-ischaemia as evidenced by the new IVU 7 sign and the damaged renal medullary papilla shown on RGP. Materials and methods: Images are reported from a series of 190 SN patients. Repeated standard imaging was invariably normal, when supine. However, 190 patients demonstrated SN of > 1.5 vertebrae on repeating IVU-E. Of whom 36 (18.9%) patients developed recurrent episodes of painful hematuria for which no organic pathology was detected on all standard imaging, when supine- thus fitting the definition of LPHS. -
Prospectus Symp19-8-2019.Indd
EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS TH INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM NOVEMBER 7-9, 2019 NEW YORK, NY MOUNTSINAIUROLOGYCME.ORG HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3-D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events Welcome to the Fourth International Prostate Cancer and Urologic Oncology Symposium. EDUCATIONAL HIGHLIGHTS • Live 3-D surgery transmission covering complex urologic surgery • Comprehensive didactic lectures from the world’s leading experts in urologic oncology • Robust review of the latest advances in surgical techniques and management of prostate, kidney, and bladder cancer • Personal interaction with world-class faculty • Stimulating point-counterpoint debates on timely topics DAILY HIGHLIGHTS PROSTATE DAY 1 THUR. 11/7/19 PROSTATE DAY 2 FRI. 11/8/19 KIDNEY & BLADDER SAT. 11/9/19 • Advanced imaging in genomics • Innovations in the management of • New progress in pre-operative and for prostate cancer castrate-sensitive prostate cancer intra-operative imaging, 3-D • Biomarkers and immunotherapy modelling, and ultra sound • Focus on radiomics and guidance for renal tumors radiogenomics • Update on clinical trials for castrate-resistant treatments for • Novel therapeutics in the • Utility of imaging and artificial prostate cancer management of metastatic renal intelligence in prostate cancer cell carcinomas: -
In the News September 30, 2016
From: ITNDaily on behalf of Werle, Laura Subject: Mount Sinai In the News - September 30, 2016 Date: Friday, September 30, 2016 2:06:09 PM Attachments: ATT00002.txt In the News September 30, 2016 Nature – September 30 Inflammation in Patients With Cushing Disease — Claire Greenhill Circulating levels of proinflammatory cytokines are increased in patients with Cushing disease, both during active disease and after remission, according to new data published in Clinical Endocrinology. These findings demonstrate that cytokine levels are increased in patients after remission of Cushing disease, which could explain the persistent increased risk of cardiovascular-related death. The study, led by Eliza Geer, MD, a professor of endocrinology at the Icahn School of Medicine at Mount Sinai, notes that more studies are needed to determine why levels of IL-6 and IL-1β remain elevated after remission of Cushing disease. - Eliza Geer, MD, Associate Professor, Medicine, Endocrinology, Diabetes and Bone Disease, Neurosurgery, Icahn School of Medicine at Mount Sinai Learn more: http://www.nature.com/nrendo/journal/vaop/ncurrent/full/nrendo.2016.170.html WCBS – September 29 ‘Artificial Pancreas’ Expected To Make Life Easier, Healthier For Type 1 Diabetes Patients — Max Gomez A groundbreaking new device could change the lives of millions of people living with diabetes. Federal regulators just approved an artificial pancreas that can monitor and administer insulin. The key is a computer algorithm that does those calculations faster and more accurately than a patient can. “It looks at the numbers from a moment to moment basis, and it will proactively predict what is going to happen next and make clinical decisions that cannot be done at that rate. -
Supermicar Data Entry Instructions, 2007 363 Pp. Pdf Icon[PDF
SUPERMICAR TABLE OF CONTENTS Chapter I - Introduction to SuperMICAR ........................................... 1 A. History and Background .............................................. 1 Chapter II – The Death Certificate ..................................................... 3 Exercise 1 – Reading Death Certificate ........................... 7 Chapter III Basic Data Entry Instructions ....................................... 12 A. Creating a SuperMICAR File ....................................... 14 B. Entering and Saving Certificate Data........................... 18 C. Adding Certificates using SuperMICAR....................... 19 1. Opening a file........................................................ 19 2. Certificate.............................................................. 19 3. Sex........................................................................ 20 4. Date of Death........................................................ 20 5. Age: Number of Units ........................................... 20 6. Age: Unit............................................................... 20 7. Part I, Cause of Death .......................................... 21 8. Duration ................................................................ 22 9. Part II, Cause of Death ......................................... 22 10. Was Autopsy Performed....................................... 23 11. Were Autopsy Findings Available ......................... 23 12. Tobacco................................................................ 24 13. Pregnancy............................................................ -
In the News July 29, 2016
From: ITNDaily on behalf of Stephanie Sherman Subject: Mount Sinai In The News - July 29, 2016 Date: Friday, July 29, 2016 11:20:39 AM Attachments: ATT00002.txt In the News July 29, 2016 WBUR News – July 28 Doctors Need A New Skill Set For This Opioid Abuse Treatment — Karen Shakerdge Braeburn Pharmaceuticals, the company behind the newly FDA-approved treatment Probuphine, is teaching doctors how to use it. Although addiction specialists welcome Probuphine, which delivers a constant dose of the drug buprenorphine over six months, at this early stage it's complicated for physicians to add it to their repertoire. Patients using Probuphine were 14 percent more likely to stay opioid-free compared to those using a daily sublingual version of buprenophine, according to a study published this month in JAMA, the Journal of the American Medical Association. So it's good to have another way to deliver medication-assisted treatment, says Richard Rosenthal, medical director of addiction psychiatry for the Mount Sinai Health System. Rosenthal was one of two principal investigators on a Probuphine clinical trial. "Everybody is waking up to the fact that we're in the midst of an opioid epidemic," says Rosenthal. "There are actually very few medications for addiction of any kind. Given the addiction treatment system in the United States, most of the treatment that's given is psychosocial. There's very little use of FDA-approved medications." - Richard N. Rosenthal. MD, Professor, Psychiatry, Mount Sinai West Learn more: http://www.wbur.org/npr/487080738/doctors-need-a-new-skill-set-for-this-opioid-abuse- treatment MD Alert – July 28 Some Non-Celiac Gluten Sensitivity Patients May Have 'Celiac Lite' Disease — Marilynn Larkin A subset of patients with non-celiac gluten sensitivity (NCGS) may actually have a form of celiac disease, researchers in Spain report. -
PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium
EXHIBITOR AND PROMOTIONAL PARTNERSHIP PROSPECTUS SEPTEMBER MOUNT SINAI HOSPITAL 7-9 NEW YORK, NEW YORK 2017 Second International Urologic Cancer Symposium HIGHLIGHTS • Over 80 renowned global faculty • Live 3D surgical demonstrations, including prostate, kidney, bladder and reconstruction • Point-Counterpoint Debate • Annual Push Up Challenge • Gala to Raise Funds for Urologic Cancer Research TOPIC AREAS • Screening and Low Risk Disease • Localized Prostate Cancer • Biomarkers and Genomics • Advanced Prostate Cancer • Immunotherapy • Kidney Cancer • Focal Therapy • Bladder Cancer www.mountsinaiurologycme.org TABLE OFCONTENTS Invitation to Exhibit/Sponsor . 1 Department of Urology 75th Anniversary Session . 2 Screening & Low Risk Disease . 3 Focal Therapy . 4 Treatment Failure . 4 Immunotherapy & Tumor Microenvironment . 5 Radical Prostatectomy . 6 Treating Localized Disease . 7 Advanced Prostate Cancer . 8 Locally Advance Disease. 9 Quality of Life . 9 Kidney Cancer - I. 10 Kidney Cancer - II . 11 Kidney Cancer - III . 12 Bladder Cancer I . 13 Partnership Information . 14 Partnership Opportunities . 15 Exhibit Registration Form . 17 Agenda. 18 Invitation to Exhibit/Sponsor 1 Course Director Dear Industry Colleagues: Ash Tewari, MBBS, MCh On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New York City, I Co –Directors would like to invite you to partner with the 2nd International Urologic Cancer Symposium being held on September On behalf of the Department of Urology at the Icahn School of Medicine at Mount Sinai Hospital in New Ketan K. Badani, MD 6-9, 2017 at the Mount Sinai School of Medicine in New York, NY. Ranked among the nation’s best for Urology York City, I would like to invite you to partner with the Second International Prostate Cancer Nina Bhardwaj, MD, PhD in the 2016-2017 "Best Hospitals" issue of U.S. -
![Curriculum Vitae [PDF]](https://docslib.b-cdn.net/cover/6044/curriculum-vitae-pdf-2146044.webp)
Curriculum Vitae [PDF]
CURRICULUM VITAE GYAN PAREEK, M.D. Academic Address: 2 Dudley Street, Suite 174 Providence, RI 02905 Academic Telephone Number: 401-444-8570 Academic Fax Number: 401-444-6947 Mobile Number: 401-537-7763 Electronic Mail Address: [email protected] EDUCATION Undergraduate: University of Pittsburgh, Pittsburgh, PA Bachelor of Science in Neuroscience, 1991 Graduate: Roswell Park Cancer Institute, SUNY at Buffalo Buffalo, NY Master of Science, 1993 Brown University Providence, RI Master of Arts ad eundem, 2014 Harvard Medical School Boston, MA 2018-Current Harvard Certificate in Leadership Medical School: St. George’s University School of Medicine, M.D., 1998 POSTGRADUATE TRAINING Residency: Lenox Hill Hospital, New York, NY Surgery (PGY1), 7/1/1998-6/30/1999 Lenox Hill Hospital, New York, NY Surgery (PGY2), 7/1/1999-6/2000 Lenox Hill Hospital, New York, NY Urology, 7/1/2000-6/30/2004 Fellowship: Laparoscopy and Endourology, University of Wisconsin, Madison, WI Clinical Instructor, 7/1/2004-6/30/2005 1 POSTGRADUATE HONORS AND AWARDS 2004 American Urological Association Pfizer Scholar 2005 Annual Essay Contest, Second Place, “Basic Science” and “Elastographic Measurements of In-Vivo Radiofrequency Ablation Lesions of the Kidney.” Endourological Society, Amsterdam, Netherlands 2006 Urology (Gold Journal) Essay Contest, Second Place, “Shockwave Lithotripsy Success Based on Skin to Stone Distance on Computed Tomography.” American Urological Association, Atlanta, Georgia 2009 The Dean’s Excellence in Teaching Award, “Urology Clinical Elective”, -
Chronic Renal Pain: an Approach to Investigation and Management
review Chronic renal pain: An approach to investigation and management Malcolm J. Dewar, MBChB, MMed, MSc, FCUrol(SA); Joseph L. Chin, MD, FRCSC Division of Urology, Western University, London, ON, Canada Cite as: Can Urol Assoc J 2018;12(6Suppl3):S167-70. http://dx.doi.org/10.5489/cuaj.5327 of dominant cysts (three cysts >4 cm). Localized tenderness with an ultrasound probe, as well as relief with percutaneous cyst aspiration, might predict an improved response to cyst Introduction de-roofing or sclerotherapy. Laparoscopic denervation of the kidney accompanied by nephropexy and renal artery embol- ization has been described, while laparoscopic nephrectomy When chronic flank pain is present, there is most often a cause can be considered in patients with end-stage renal disease. that is readily identified on routine assessment (Table 1). In the vast majority of cases, resolution of the underlying pathology Loin pain hematuria syndrome (LPHS) results in improvement of the pain. Although epidemiological data are sparse, it seems that chronic renal pain syndromes LPHS is a very rare condition, characterized by intermit- are uncommon. This brief review will address selected condi- tent or persistent flank pain that is often, but not always, tions in which chronic pain is a primary presenting feature, accompanied by hematuria. Hematuria, microscopic or and give an approach to diagnosis and management. macroscopic, appears to be glomerular in origin. Pain can be severe and unrelenting, with a significant impact on quality Autosomal-dominant polycystic kidney disease (ADPKD) of life and the ability to function. The clinical syndrome has been well-characterized as follows: a six-month or longer Chronic renal pain is the most common presenting symptom history of flank pain that is either persistently present or of ADPKD. -
Signs and Symptoms of Urinary System Diseases
SIGNS AND SYMPTOMS OF URINARY SYSTEM DISEASES LECTURE IN INTERNAL MEDICINE PROPAEDEUTICS M. Yabluchansky, L. Bogun, L.Martymianova, O. Bychkova, N. Lysenko, N. Makienko, E. Tomina, E. Golubkina V.N. Karazin National University Medical School’ Internal Medicine Dept. http://kottke.org/tag/infoviz Plan of the lecture • The importance(value) of a human kidney • Reminder – how do kidneys work – the primary function – purpose • History-taking • Patient’s examination – clinical – laboratory – instrumental • Spectrum of urinary system diseases • Urinary system diseases’ symptoms and syndromes – symptoms – urinary syndrome – nephrotic syndrome – nephritic syndrome – urinary tract obstruction syndrome – hypertensive syndrome • Glossary of urinary pathology’ terms http://images.emedicinehealth.com/images/illustrations/urinary_structures.jpg The price of a human kidney The human kidney is the body’s filter. It cleans 180 liters of liquid per day, retaining the good stuff and expelling the bad. Most fortuitously, humans are born with two kidneys. If one of them becomes damaged, the other one can pick up the slack. If both your kidneys fail, however, your body will be filled with harmful toxins. Without medical intervention, such patients will die within several weeks Reminder: how kidneys work https://www.youtube.com/watch?v=aj-gbnOB4jM http://venturebeat.com/wp-content/uploads/2012/08/kidneys.jpg Reminder: the primary urinary system functions • maintain homeostasis • regulate fluids and electrolytes • eliminate waste products • maintain blood pressure (BP) • involved with red blood cell (RBC) production • involved with bone metabolism Reminder: purpose • General evaluation of health • Diagnosis of disease or disorders of the kidneys or urinary tract • Diagnosis of other systemic diseases that affect kidney function • Monitoring of patients with diabetes • Screening for drug toxicity (eg. -
336 Naegeli's
336 INDEX N Naegeli's Narrowing - continued - disease 287.1 - artery NEC - continued - leukemia, monocytic (M9863/3) 205.1 -- cerebellar 433.8 Naffziger's syndrome 353.0 -- choroidal 433.8 Naga sore (see also Ulcer, skin) 707.9 -- communicative posterior 433.8 Nagele's pelvis 738.6 -- coronary 414.0 - with disproportion 653.0 --- congenital 090.5 -- causing obstructed labor 660.1 --- due to syphilis 093.8 -- fetus or newborn 763.1 -- hypophyseal 433.8 Nail - see also condition -- pontine 433.8 - biting 307.9 -- precerebral NEC 433.9 - patella syndrome 756.8 --- multiple or bilateral 433.3 Nanism, nanosomia (see also Dwarfism) -- vertebral 433.2 259.4 --- with other precerebral artery 433.3 - pituitary 253.3 --- bilateral 433.3 - renis, renalis 588.0 auditory canal (external) 380.5 Nanukayami 100.8 cerebral arteries 437.0 Napkin rash 691.0 cicatricial - see Cicatrix Narcissism 302.8 eustachian tube 381.6 Narcolepsy 347 eyelid 374.4 Narcosis - intervertebral disc or space NEC - see - carbon dioxide (respiratory) 786.0 Degeneration, intervertebral disc - due to drug - joint space, hip 719.8 -- correct substance properly - larynx 478.7 administered 780.0 mesenteric artery (with gangrene) 557.0 -- overdose or wrong substance given or - palate 524.8 taken 977.9 - palpebral fissure 374.4 --- specified drug - see Table of drugs - retinal artery 362.1 and chemicals - ureter 593.3 Narcotism (chronic) (see also Dependence) - urethra (see also Stricture, urethra) 598.9 304.9 Narrowness, abnormal. eyelid 743.6 - acute NEC Nasal- see condition correct -
DISEASES of the Genito-Urinary Tract in In- the First One Was Removed at Operatioin (Fig
TiiE 1938 CANADIAN MEDIcALAssoCIATION JOURNAL 320 Tm. CANADIAN MEDICAL ASSOCIATION [April URINARY OBSTRUCTION IN CHILDREN* BY DAVID W. MACKENZIE AND MAX RATNER Montreal DISEASES of the genito-urinary tract in in- The first one was removed at operatioin (Fig. 1). It shows a destroyed kidney with a large dilated fants and children are sufficiently common ureter. There are three definite obstructive lesions to rate them among the important lesions of present. One is at the uretero-pelvic junction, another at the junction of the middle and lower thirds of the early life. Repeated studies have revealed that ureter, and a third (not shown on the photograph) children are subje-t to practically the same near the ureteral orifice. We feel justified in saying that if the obstructions had been recognized at an urological diseases as adults. However, the most early date proper procedures could have been carried common lesions found in the urinary tract of out, thus preventing the complete destruction of both kidney and ureter. the young are obstructive in type, and the great The second specimen was found at autopsy (Fig. majority of them result from anomalous de- 2). The child, male, aged 9 years, was admitted to the hospital in uraemia. A diagnosis of bilateral velopment. When one realizes that the incidence pyonephrosis and pyo-ureter was made. He died of congenital anomalies in the genito-urinary shortly after. The post-mortem examination revealed completely destroyed kidneys, large dilated ureters, tract is higher than in any other system of the trabeculations and diverticula of the bladder, and body it can be appreciated why the greatest finally a cyst in the posterior urethra. -
KIDNEY DISEASES Filtration
VLA, November 28, 2017 PATHOPHYSIOLOGICAL ASPECTS OF RENAL FUNCTIONS. KIDNEY DISEASES Filtration Reabsorbtion Secretion KIDNEY - FUNCTION NEPHRON: THE GLOMERULUS Reabsorpce v Henleově kličce Insert fig. 17.15 DISTAL TUBULE TUBULAR RESORPTION Proximal Tubules: GF: 120-125 mL/min Reabsorption of Na (55%), Cl, phosphate, amino acids, glucose and bicarbonate (85%). Secretion of proton (CA) Loop of Henle: (30 mL/min) Na/K/2Cl Cotransporter (25% Na reabsorbed) Water impermeable: Hypertonic medullary inst Ca & Mg paracellular diffusion Distal Tubules: EDT: Na/Cl cotransporter; Ca/Na counter transport LDT: Na Channels, K channels, H pump: Aldosterone reg. Collecting Tubules: 5-10 mL/min Water channels: Vasopressin regulated Ureters: 1-2 mL/min (stored inbladder until voiding) SUMMARY OF TUBULAR RESORPTIVE PROCESSES SYSTEM RENIN-ANGIOTENSIN -ALDOSTERON RPR, renin/prorenin receptor; Mas, mas oncogene, receptor for Ang 1–7; AT2R, angiotensin type 2 receptor AT1R, angiotensin type 1 receptor, IRAP, insulin-regulated aminopeptidase; Ang IV receptor AMPA, aminopeptidase A; AMPM, aminopeptidase M; ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; NEP, neutral endopeptidase. PRORENIN INTERACTION WITH RENIN/PRORENIN RECEPTOR (RPR, NGUYEN 2007 ) SYSTEM RENIN-ANGIOTENSIN 11β-HSD2 = 11β-hydroxy steroid dehydrogenase, type 2 Vasopressin function . Stimulation of V2 receptor for ADH causes aquaporin2 insertion (using cAMP second messenger) to apical membrane which enables water transport along the osmotic gradient. REGULATION